ATAXIA UK — grant history
Latest income
£1.8m
Grants listed (FY2025)
2
Listed grants total
£78k
Accounts grants total
£78k
listed grants reconcile with the accounts totalextracted from its FY2025 accounts
Application guidance — from the funder’s own website
- How to apply: Ataxia UK does not accept unsolicited applications for research grants. The charity funds a wide variety of research projects, but the specific process for researchers to apply is not detailed on the provided pages, which only list currently funded projects.
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Z-Institut du Cerveau et de laMoelle épinière-ICM | FY2025 | £68k | Novel biomarkers of oxidative stress in ataxia; Identification of disease-associated single nucleotide polymorphisms in ataxin-3; Evaluating ribosome collisions on CAG expansions proteostasis and translational; Consultancy support with respect to preparing for Health Technology Assessment; Effect of targeting sphingolipid- metabolising enzymes in iPSC-derived sensory neurons model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) |
| Z-Universidade de Lisboa | FY2025 | £10k | Restoring NKX6-2 function by protein complementation: a proof-of-concept; Outcome measures in Mitochondrial disease and Spinocerebellar ataxias (R-PROMS) |
| Prof Marios Hadjivassiliou (Sheffield Teaching Hospitals NHS Trust, UK) | FY2023 | £38k | Improving the diagnosis and management of gluten ataxia |
| Dr Karen Anthony (University of Northampton, UK) | FY2023 | £31k | Evaluation of RNA trans-splicing as a therapeutic strategy for spinocerebellar ataxia type 1 |
| Dr Andreia Teixeira-Castro (University of Minho, Portugal) | FY2023 | £30k | Testing the multimodal anti-depressant vortioxetine as a therapeutic strategy to mitigate SCA3 |
| Dr Roderick Maas (Radboud University Medical Center, The Netherlands) | FY2023 | £30k | Looking beyond the central nervous system in SCA3: nerve and muscle ultrasound as potential imaging markers to quantify and monitor peripheral nervous system degeneration. |
| Prof Paola Giunti (University College London, UK) | FY2023 | £27k | Validating the therapeutic effect, a CAG repeat-targeting antisense oligonucleotide, on mitochondrial physiology in cellular models of DRPLA |
| Prof Paola Giunti (University College London, UK) | FY2023 | £25k | Determine mitochondrial metabolism in DRPLA: a possible novel therapeutic approach |
| UK Researchers | FY2023 | £7k | Nine bursaries of £750 each to UK researchers to help them attend the International Congress for Ataxia Research |
| Dr Francesca Salvatori (University of Ferrara, Italy) | FY2023 | £5k | Personalized gene editing approach for the treatment of Spinocerebellar Ataxia type 1 (SCA1) |
| Dr Pellerin (UCL) | FY2023 | £2k | Dr David Pellerin travel grant award of £1500 to attend and present an oral presentation at the American Academy of Neurology 2023 Annual Meeting. |
| Gordon Research Conference | FY2023 | £433 | $500 Sponsorship of CAG Triplet Repeat Disorders Gordon Research Conf and Seminar |
| University of North Carolina at Chapel Hill, USA | FY2022 | £131k | DRPLA Natural History and Biomarkers Study (DRPLA NHBS) |
| German Center for Neurodegenerative Diseases, Bonn, Germany | FY2022 | £80k | Assessment of ataxia severity under real-life conditions with SARAhome: A multicenter study in spinocerebellar ataxia type 3 (SCA3) |
| Institut du Cerveau et de la Moelle épinière (ICM), France | FY2022 | £61k | Preclinical development of an amelioration therapy for DentatorubroPallidoluysian Atrophy – Funding Extension |
| Instituto de Invesigacão e Inovacão em Saúde – i3S, Portugal | FY2022 | £30k | NanoSCA3: Development of brain-targeted nanobodies for application in spinocerebellar ataxia type 3 therapy |
| University of Brescia, Italy | FY2022 | £5k | Motor and cognitive outcomes of non-invasive transcranial alternate current stimulation by entrainment of cerebellar oscillation |
| University College London, UK | FY2022 | £5k | Brain pathology in an AIFM1 mutation causing Cowchock syndrome |
| Imperial College London, UK | FY2022 | £5k | Generation and characterization of a cardiomyocyte model for Friedreich’s ataxia to reveal the molecular mechanism of heart failure in patients |
| Newcastle University, UK | FY2022 | £5k | Balance and gait abnormalities in adult patients with mitochondrial disease and spinocerebellar ataxia type 6 |
| Centro de Biología Molecular Severo Ochoa, Madrid, Spain | FY2022 | £5k | Analysis of the mitochondrial dysfunction in FXN deficient neurones to generate a drug screening test |
| Strathclyde University, UK | FY2022 | £3k | A feasibility study of LSVT Artic to improve speech performance in people with progressive ataxia |